These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 16531988)

  • 21. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 22. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
    Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
    Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HIF and other quandaries in VHL disease.
    Tarade D; Ohh M
    Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
    Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
    IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.
    Rohan SM; Xiao Y; Liang Y; Dudas ME; Al-Ahmadie HA; Fine SW; Gopalan A; Reuter VE; Rosenblum MK; Russo P; Tickoo SK
    Mod Pathol; 2011 Sep; 24(9):1207-20. PubMed ID: 21602815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL.
    Li M; Kim WY
    J Cell Mol Med; 2011 Feb; 15(2):187-95. PubMed ID: 21155973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxygen sensors and angiogenesis.
    Maxwell PH; Ratcliffe PJ
    Semin Cell Dev Biol; 2002 Feb; 13(1):29-37. PubMed ID: 11969369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
    Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
    Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular targets from VHL studies into the oxygen-sensing pathway.
    Maynard MA; Ohh M
    Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI; Jewett MA; Ohh M
    Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
    Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
    Knauth K; Bex C; Jemth P; Buchberger A
    Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.
    Takamori H; Yamasaki T; Kitadai R; Minamishima YA; Nakamura E
    Cancer Sci; 2023 Apr; 114(4):1208-1217. PubMed ID: 36650918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
    Kaelin WG
    Trans Am Clin Climatol Assoc; 2017; 128():298-307. PubMed ID: 28790514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.